Torres, Tiago, Puig, Lui, Vender, Ron, Yeung, Jensen, Carrascosa, José-Manuel, Piaserico, Stefano, Gisondi, Paolo, Lynde, Charle, Ferreira, Paulo, Bastos, Pedro Mende, Dauden, Esteban, Leite, Luiz, Valerio, Joana, Del Alcázar-Viladomiu, Elena, Rull, Eva Vilarrasa, Llamas-Velasco, Mar, Pirro, Federico, Messina, Francesco, Bruni, Manfredo, Licata, Gaetano, Ricceri, Federica, Nidegger, Alessia, Hugo, Jan, Mufti, Asfandyar, Daponte, Athina-Ioanna, Teixeira, Laetitia, Balato, Anna, Romanelli, Marco, Prignano, Francesca, Gkalpakiotis, Spyridon, Conrad, Curdin, Lazaridou, Elizabeth, Rompoti, Natalia, Papoutsaki, Marina, Nogueira, Miguel, Chiricozzi, Andrea, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), Torres, Tiago, Puig, Lui, Vender, Ron, Yeung, Jensen, Carrascosa, José-Manuel, Piaserico, Stefano, Gisondi, Paolo, Lynde, Charle, Ferreira, Paulo, Bastos, Pedro Mende, Dauden, Esteban, Leite, Luiz, Valerio, Joana, Del Alcázar-Viladomiu, Elena, Rull, Eva Vilarrasa, Llamas-Velasco, Mar, Pirro, Federico, Messina, Francesco, Bruni, Manfredo, Licata, Gaetano, Ricceri, Federica, Nidegger, Alessia, Hugo, Jan, Mufti, Asfandyar, Daponte, Athina-Ioanna, Teixeira, Laetitia, Balato, Anna, Romanelli, Marco, Prignano, Francesca, Gkalpakiotis, Spyridon, Conrad, Curdin, Lazaridou, Elizabeth, Rompoti, Natalia, Papoutsaki, Marina, Nogueira, Miguel, Chiricozzi, Andrea, and Chiricozzi, Andrea (ORCID:0000-0002-6739-0387)
Background: Drug survival, defined as the length of time from initiation to discontinuation of a given therapy, allows comparisons between drugs, helps to predict patient's likelihood of remaining on a specific treatment, and achieving the best decision for each patient in daily clinical practice. Objective: The aim of this study was to provide data on drug survival of secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab in a large international cohort, and to identify clinical predictors that might have an impact on the drug survival of these drugs. Methods: This was a retrospective, multicentric, multi-country study that provides data of adult patients with moderate to severe psoriasis who started treatment with an interleukin (IL)-17 or IL-23 inhibitor between 1 February 2015 and 31 October 2021. Data were collected from 19 distinct hospital and non-hospital-based dermatology centers from Canada, Czech Republic, Italy, Greece, Portugal, Spain, and Switzerland. Kaplan-Meier estimator and proportional hazard Cox regression models were used for drug survival analysis. Results: A total of 4866 treatment courses (4178 patients)-overall time of exposure of 9500 patient-years-were included in this study, with 3164 corresponding to an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab) and 1702 corresponding to an IL-23 inhibitor (guselkumab, risankizumab, tildrakizumab). IL-23 inhibitors had the highest drug survival rates during the entire study period. After 24 months of treatment, the cumulative probabilities of drug survival were 0.92 (95% confidence interval [CI] 0.89-0.95) for risankizumab, 0.90 (95% CI 0.88-0.92) for guselkumab, 0.80 (95% CI 0.76-0.84) for brodalumab, 0.79 (95% CI 0.76-0.82) for ixekizumab, and 0.75 (95% CI 0.73-0.77) for secukinumab. At 36 months, only guselkumab [0.88 (95% CI 0.85-0.91)], ixekizumab [0.73 (95% CI 0.70-0.76)], and secukinumab [0.67 (95% CI 0.65-0.70)] had more than 40 patients at risk of drug discon